Quick Update for Vaxcyte (PCVX) Investors

By Scott Lee • Friday, January 05 15:14 • Permanent Link

Vaxcyte marked a -7.3% change today, compared to -0.0% for the S&P 500. Is it a good value at today's price of $59.66? Only an in-depth analysis can answer that question, but here are some facts that can give you an idea:

Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases.
Vaxcyte belongs to the Health Care sector, which has an average price to earnings (P/E) ratio of 30.21 and an average price to book (P/B) of 4.08
The company's P/B ratio is 4.04
Vaxcyte has a trailing 12 month Price to Earnings (P/E) ratio of -12.6 based on its trailing 12 month price to earnings (EPS) of $-4.73 per share
Its forward P/E ratio is -13.9, based on its forward earnings per share (EPS) of $-4.3
PCVX has a Price to Earnings Growth (PEG) ratio of 0.58, which shows the company is very undervalued compared to its earnings growth estimates.
Over the last four years, Vaxcyte has averaged free cash flows of $-107488500.0, which on average grew -54.7%
Vaxcyte has moved 37.9% over the last year compared to 20.4% for the S&P 500 -- a difference of 17.5%
PCVX has an average analyst rating of buy and is -15.77% away from its mean target price of $70.83 per share

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.